Ilse Treurnicht has been a member of Triphase’s Board of Directors since 2010
and currently serves as Executive Chairperson, working closely with Triphase's Senior Management team to support the company’s strategic planning and key decision-making processes. Most recently, Ilse Treurnicht was CEO of MaRS Discover District, a 1.5-million-sq.-ft. innovation hub located in Toronto. MaRS works with partners to catalyze, accelerate, scale and diffuse innovation in the areas of health, energy & environment, finance & commerce, and work & learning. MaRS supports innovators and entrepreneurs building high-impact growth businesses, offering specialized infrastructure as well as access to critical talent, capital and customer networks. Ilse joined MaRS in early 2005 from her role as President & CEO of Primaxis Technology Ventures, a startup-stage venture capital fund focused on the advanced technologies sector. Prior to Primaxis, Ilse was an entrepreneur with senior management roles in a number of emerging technology companies. Ilse holds a DPhil in chemistry from Oxford University, which she attended as a Rhodes scholar.
Dr. David O’Neill is the President of FACIT and has been a member of Triphase’s Board of Directors since 2018.
Dr. O’Neill has extensive experience in Pharma, Biotech and seed stage investing, including a wealth of networks and transaction experience through various business development roles at AstraZeneca, Ambit Biosciences (Daiichi Sankyo), Kinomescan (Discoverx/Eurofins), Fluorinov Pharma (Trillium Therapeutics). He also held operational roles including non-clinical safety, IND submission and Project Leader during clinical development of Quizartinib. He has provided interim executive management to FACIT spin outs Turnstone Biologics, Propellon and Novera Therapeutics. In addition to serving on the Board of Turnstone, he is also a Board Observer for Fusion Pharmaceuticals. Dr. O’Neill holds a PhD from Western University from the Faculty of Health Sciences with an emphasis on heat shock protein biology.
Dr. Hofstein is the President of MaRS Innovation (MI)
and has been a member of Triphase’s Board of Directors since 2010. MI is a non-profit organization that acts on behalf of its members–15 of Toronto’s top universities, institutions and research institutes, plus the MaRS Discovery District–to bring their most promising research breakthroughs to market.
Dr. Hofstein received his PhD and Master of Science degrees in Life Sciences and Chemistry from the Weizmann Institute of Science in Rehovot, Israel. His Bachelor of Science degree in Chemistry and Physics was attained from the Hebrew University in Jerusalem. Awards received while completing postdoctoral training and research at the Harvard Medical School in Boston in the Departments of Biological Chemistry and Neurobiology include the Hereditary Disease Foundation Fellowship in 1982-83, and the Chaim Weizmann Postdoctoral Fellowship in 1980-82. During the 1980s, he held the roles of Scientific Director of Biotechnological Applications Ltd., and Manager R&D and Chief of Immunochemistry at the International Genetic Scientific Partnership; organizations that were pivotal in the development of Israel’s world-leading biotechnology sector. Dr. Hofstein was Scientific Director of the Israeli office of Ecogen Inc., a subsidiary of Monsanto, for over six years before assuming the role of Vice President, Business Development for Ecogen in Langhorne, Pa. From 1997 to 1999 Dr. Hofstein was President of Mindsense Biosystems Ltd., an Israeli company that develops neuropsychiatric immune assays. From 1999 to the present, he has held the position of President and CEO of Hadasit Ltd., the technology transfer company of the Hadassah Medical Organization in Jerusalem. Later on, Dr. Hofstein joined Medica Ventures, a lead VC in Israel and served for 10 years as the President and CEO of Hadasit, the commercialization company of Hadassah, the largest teaching hospital in Israel. Dr. Hofstein was the founder and served as Chair of Hadasit BioHolding Ltd., a publicly traded holding company (10 startups under management) on the Tel Aviv Stock Exchange (TASE), since 2005. Other directorships held on TASE publicly traded companies include: Bioline RX (drug development); Exalenz (medical devices); and Evogene (agri-bio). He has also served as Chairman of BIOMED, Israel’s annual biomedical conference, from 2005 to 2007. In addition, Dr. Hofstein is a co-founder and board member of ILSI, the Israeli Life Science Industry Organization, and a co-founder and executive in Israel’s Tech Transfer Network (ITTN). Dr. Hofstein is currently member of the board of directors of Life Science Ontario and of Clinical Trials Ontario as well as a member of the Organizing Committee of the Public Policy Forum (part of the Quebec City Conference).
Dr. Schmidt joined Triphase in 2019
with more than 20 years of global biopharmaceutical industry experience in executive management focused on the research and development of biotherapeutics and pharmaceuticals. Most recently he was CEO of ArmaGen, Inc., a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Prior to ArmaGen, he held various positions with Takeda Pharmaceuticals and its subsidiaries from 2001 to 2016, including oncology drug discovery, early alliance management and overseeing biologics. He joined Takeda California in 2012 as Vice President of Biological Sciences where he built a highly functional Biotherapeutics unit serving all therapeutic indications and all research sites within the global Takeda organization. In 2011, he was awarded the venia legendi in pharmacology from the University of Konstanz. He and his team developed a HER-2 specific immunotoxin that subsequently entered the clinic during his tenure at the Tumor Biology Centerat the University of Freiburg. After working for several years at various cancer hospitals in Germany and the U.S., he joined the pharmaceutical industry in 1999, where he developed a great passion for drug discovery and development, especially for protein therapeutics. He holds an M.S. degree in Biotechnology from the University of Stuttgart (Germany) and a Ph.D. in Tumor Biology (summa cum laude) from the University of Freiburg. He is a lecturer of cellular biology and pharmacology at the University of Constance.
Nancy Levin joined Triphase in 2015
with more than 20 years’ experience in the biotechnology industry, and technical expertise in clinical and translational pharmacology and nonclinical development. Nancy was Vice President of Therapeutics Product Design Group at Intrexon Corporation (2013-2014), where she oversaw the conception and development of novel therapeutic partnering opportunities enabled by Intrexon’s proprietary cell- and DNA-based technologies. Prior to this, Nancy held positions of increasing responsibility at Pfizer (CovX Research, 2005-2013), X-Ceptor Therapeutics (2003-2004), MitoKor (2001-2003), and Trega Biosciences (1999-2001). Nancy’s biotechnology experience began at Genentech (1993-1996), followed by Amgen (1996-1999), where she led multiple discovery and target validation projects. Her breadth of therapeutic area expertise includes oncology, metabolic and cardiovascular diseases, dermatology, inflammation, endocrinology, and rare/ultra-rare genetic diseases. She has led programs from discovery into clinical proof-of-concept employing multiple therapeutic modalities including small molecules, antibody-drug and -peptide conjugates, peptides, proteins, and antibodies. Nancy’s development experience includes 19 IND/CTA filings, and 11 Phase 1 and 6 Phase 2 clinical proof-of-concept studies, responsible for clinical PK and biomarker study design and execution, PK modeling, clinical efficacy and safety data analysis and presentation, clinical protocol design and development, IND and Orphan Drug applications and annual reports, and complete IND-enabled submission packages for small and large molecules. She earned a Ph.D. in Endocrinology at the University of California San Francisco, followed by post-doctoral training in the Fishberg Research Center for Neurobiology at The Mount Sinai School of Medicine in New York, NY.
Grant Gibson joined Triphase in 2012
and has more than 20 years of experience focused on the biotech, pharma and life science industries, with expertise in corporate strategy, M&A, finance and operations. Throughout his career Grant has led several strategic and operational endeavours, including several biotech collaboration and licensing transactions, divestitures and acquisitions, post-acquisition integrations and new company start-ups. Prior to joining Triphase, Grant was the CFO of Clearstone Central Laboratories – a private global central laboratory business spun-out from MDS Inc. Before joining Clearstone, Grant held senior finance positions with MDS Inc. – a public global CRO business, and Elan Pharmaceuticals – a global public pharmaceutical company focused on neurodegenerative and autoimmune diseases. Prior to entering industry, Grant was a valuation expert for Deloitte & Touche in San Francisco, providing valuation consulting services to many leading global pharma/biotech and technology companies. Grant began his career with Ernst & Young and held various positions of increasing responsibility in the firm’s Corporate Finance and Audit & Assurance practice areas in both Canada and the United States. Grant obtained his Honors Business Administration (HBA) degree from the Richard Ivey School of Business at the University of Western Ontario and is a Chartered Professional Accountant (CPA) and Chartered Business Valuator (CBV).
Henry Lowman joined Triphase in 2015
with more than 25 years’ experience in the biotechnology industry and technical expertise in antibody and protein engineering. In 2013 he was named one of the top 25 most influential people in the antibody field by Total Biopharma. He headed the CytomX Therapeutics research organization as vice president of research and later chief scientific officer (2010-2014) in work on the Probody™ platform. Prior to that, Dr. Lowman was director of protein sciences at NGM Biopharmaceuticals (2009-2010) and served a 20-year tenure at Genentech (1989-2009), where he focused on the research and development of protein and antibody therapeutics. Following a postdoc at Genentech, he moved on to roles as scientist and senior scientist, before leading Genentech's antibody engineering department, with research and early-development team-leader roles in several therapeutic antibody programs, including VEGF, IgE and CD20 antibodies. His career interests include structure-based drug design, structure-function analysis and molecular diversity techniques. Dr. Lowman is an author on more than 70 scientific publications, an inventor on more than 80 issued U.S. patents, and an editorial board member for the antibody journal mAbs. He earned a B.A. in chemistry at the Johns Hopkins University and Ph.D. in chemistry at Purdue University before being named an NIH postdoctoral fellow at Genentech.